
    
      This is an observational phase IV study evaluating Niraparib as maintenance treatment in
      patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real
      life setting. Will be enrolled all patients who have been part of the Italian Compassionate
      Use Program (CUP) prior to participating in this study. Once the CUP will be closed the trial
      will continue with th prospective collection of data of patients treated with Niraparib
      according to the label for 2 years.
    
  